Xpreza is a medication used primarily in the management of blood disorders such as myelodysplastic syndromes (MDS). It contains Azacitidine, a chemotherapy agent that works by interfering with the growth of abnormal cells in the bone marrow, allowing normal blood cell production. Azacitidine belongs to a class of drugs called antimetabolites. It incorporates into the DNA and RNA of abnormal cells, inhibiting their replication and promoting the restoration of normal bone marrow function.

Indications: Xpreza is prescribed for-

• Myelodysplastic Syndromes (MDS)
• Chronic Myelomonocytic Leukemia (CMML)
• Acute Myeloid Leukemia (AML) in certain cases
• Treatment of other marrow-related abnormalities as determined by a healthcare provider

Common side effects: Nausea and vomiting, Fatigue and weakness, Decreased blood cell counts (anemia, neutropenia, thrombocytopenia), Fever or signs of infection.

Precautions

• Monitoring: Regular blood tests are essential to monitor blood cell counts and liver function.
• Pregnancy and Breastfeeding: Xpreza  is not recommended during pregnancy or breastfeeding due to its potential effects on the fetus or infant.
• Interactions: Inform your doctor about any other medications you are taking to avoid interactions.

Storage

• Store Xpreza in a refrigerator at 2–8°C. Do not freeze.

Route of Administration: Subcutaneous or intravenous injection.

Dosage: The usual starting dose is 75 mg/m² body surface area, administered daily for 7 days. The exact dosage and treatment cycle depend on the patient's condition and response.

Preparation: The powder is reconstituted with sterile water for injection as per the manufacturer's instructions.